Table 3.

Univariate and multivariate analysis of DRP1 expression and overall survival, and disease‐free survival.

Variable	Overall survival				Disease‐free survival
	Univariate analysis		Multivariate analysis		Univariate analysis		Multivariate analysis
	HR (95% CI)	P‐value	aHR* (95% CI)	P‐value	HR (95% CI)	P‐value	aHR* (95% CI)	P‐value
Age (≤ 60 vs > 60)	3.1 (0.9–10.5)
Gender (female vs male)	2.7 (0.6–11.7)	0.182	4.3 (0.92–20.4)	0.064	1.6 (0.6–4.3)	0.39
Cancer site
Oropharynx vs oral	0.7 (0.2–2.4)	0.589			1.2 (0.6–2.3)	0.571	1.6 (0.8–3.2)	0.149
Hypopharynx & larynx vs oral	1.0 (0.2–4.2)	0.956			1.7 (0.8–3.7)	0.157	1.5 (0.7–3.3)	0.303
pT status (T3–T4 vs T1–T2)	2.2 (0.9–5.2)	0.071	2.0 (0.8–4.7)	0.129	1.8 (1.04–3.0)	0.033	2.0 (1.2–3.5)	0.013
pN status (N1–N3 vs N0)	0.7 (0.3–1.8)	0.48			1.0 (0.6–1.7)	0.883
Clinical stage (III–IV vs I–II)	1.3 (0.5–3.3)	0.559			1.1 (0.6–1.8)	0.81
Adjuvant Tx (Yes vs No)	1.1 (0.5–2.6)	0.869			0.8 (0.5–1.3)	0.312
DRP1 expression (High vs low)	5.8 (2.1–16.0)	0.001	6.5 (2.2–18.5)	0.001	3.3 (1.9–5.6)	< 0.001	3.5 (2.0–6.1)	< 0.001

^*aHR, HR adjusted variables where P‐value of univariate analysis was < 0.200.